Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of High-Dose Quadrivalent Influenza Vaccine (Efluelda®) Versus Standard-Dose (QIV-SD), in Subjects 65 Years of Age and Older on Innate Immunity, Including Gene Expression

NCT05154383 is registered in ClinicalTrials.gov with Centre Hospitalier Annecy Genevois as lead sponsor.

NCT NCT05154383
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05154383 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of High-Dose Quadrivalent Influenza Vaccine (Efluelda®) Versus Standard-Dose (QIV-SD), in Subjects 65 Years of Age and Older on Innate Immunity, Including Gene Expression
Lead sponsor
Centre Hospitalier Annecy Genevois
Phase
Phase 4
Overall status
Completed
Start date
November 15, 2021
Completion date
July 21, 2022
Enrollment
60 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

vaccine reaction